RIGEL PHARMACEUTICALS INC
Company Stats
- Market Cap
- $899.4M
- as of Sep 30, 2026
- Enterprise Value
- $911.4M
- Shares Outstanding
- 18.7M
- Free Float
- 73.6%
Income Statement
- Revenue
- $294.3M
- Operating Income
- $125.5M
- Net Income
- $367.0M
- EBITDA
- $127.9M
- Revenue Growth, 3Y
- 34.8%
Balance Sheet
- Cash & Equivalents
- $40.6M
- Total Debt
- $52.5M
- Net Debt
- $11.9M
- Net Debt / EBITDA
- 0.09x
- EV / EBITDA
- 7.13x
- Net Debt / EBIT
- 0.10x
Returns & Capital
- SBC, 3Y Avg
- $11.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $294.3M | — | — |
| FY2024 | $179.3M | — | — |
| FY2023 | $116.9M | — | — |
| FY2022 | $120.2M | -$74.2M | -61.7% |
| FY2021 | $149.2M | $5.3M | 3.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 26, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back